Chargement en cours...
Development and characterization of liposomal formulation of bortezomib
Bortezomib is a proteasome inhibitor used for the treatment of multiple myeloma. The poor pharmacokinetic profile and off-target adverse effects provide a strong incentive to develop drug delivery systems for bortezomib. In the past, liposomal encapsulation has been proven to improve the therapeutic...
Enregistré dans:
| Publié dans: | Int J Pharm X |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6733293/ https://ncbi.nlm.nih.gov/pubmed/31517276 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijpx.2019.100011 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|